Mineral Nanorods for Cisplatin Delivery Research
Official patent title
Synthesis and characterization of glauconite-based silicate nanorods as anticancer agent
Arabic title: تصنيع وتوصيف قضبان نانوية من السيليكات القائمة على الغلوكونيت بوصفها عاملًا مضادًا للسرطان
Invention
Invention
Problem
Cisplatin is effective against several cancers but can cause substantial toxicity, motivating research into carriers that control loading and release. Natural glauconite has useful layered and ion-exchange properties but has been less developed as a medical nanocarrier.
Why it matters
A porous mineral-derived carrier may offer a new platform for controlled cisplatin-delivery research. The reported loading, release, and cancer-cell results are preclinical and do not establish safety or efficacy in animals or patients.
Approach
The process exfoliates natural glauconite, converts the layers into rolled aluminum-silicate nanorods through solvent treatment, surfactant intercalation, and prolonged sonication, then loads the porous rods with cisplatin for pH-dependent release and in-vitro cytotoxic contact.
Who may benefit
Potential beneficiaries include nanomedicine and clay-mineral researchers, oncology drug-delivery teams, preclinical formulation laboratories, and materials organizations developing mineral-based carriers.
Potential value
The patent combines an abundant mineral feedstock with a defined nanorod-manufacturing route and reports structural characterization, cisplatin-loading capacity, pH-dependent extended release, and in-vitro cancer-cell viability data.
Background
Background
Platinum chemotherapy can damage healthy tissue and produce serious adverse effects, encouraging development of delivery carriers. Clay minerals offer layered structures, surface area, porosity, and ion-exchange capacity, and rolled clay nanosheets can provide additional loading sites. Most prior exfoliation and scrolling work cited in the patent focused on kaolinite and bentonite. Glauconite is a metal-bearing, layered mineral with useful surface and exchange properties, but its use as a cancer-drug carrier has been limited. The disclosure converts it into porous silicate nanorods and loads them with cisplatin.
Technology overview
Technology overview
Ground glauconite is dispersed for 70–75 hours, washed with methanol, intercalated with cetyltrimethylammonium bromide for 45–50 hours, and sonicated at 230–250 W for 90–100 hours to roll exfoliated sheets into nanorods. Claimed rods are 100–5500 nm long, 20–250 nm in diameter, and have 1–12 nm pores. They load cisplatin through surface and pore interactions, with reported capacities up to 200–350 mg/g, pH-dependent release over roughly 100–210 hours, and in-vitro viability measurements.
Potential applications
Potential applications
- Preclinical cisplatin-delivery and controlled-release research.
- pH-dependent drug-release studies using porous mineral nanorods.
- In-vitro oncology testing of drug-loaded silicate carriers.
- Development of glauconite-derived nanomaterials for biomedical research.
Evidence-supported advantages
Evidence-supported advantages
- Uses natural glauconite as the starting mineral feedstock.
- Creates porous rolled nanorods with specified dimensions and surface characteristics.
- Reports cisplatin loading capacities up to 200–350 mg/g.
- Documents different extended-release periods under acidic and near-neutral pH.
- Includes structural imaging and in-vitro cancer-cell viability measurements.
Development stage
Development stage
Nanorod synthesis, structural characterization, cisplatin loading and release, and in-vitro cell testing are described; clinical performance and commercialization were not established.
Commercial opportunity
Commercial opportunity
The platform may support research partnerships with nanomedicine, mineral-material, and oncology-formulation groups. Advancement would require scalable processing, removal of residual reagents, batch consistency, sterilization, biodistribution and toxicity studies, in-vivo efficacy, and regulatory evaluation. Comparisons with free cisplatin and other carriers would be necessary.
Patent classifications
Patent classifications
WIPO IPC
- A61K47/69Preparations for medical, dental or toiletry purposes
- A61K33/243Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
CPC
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
- A61K9/0092Preparations for medical, dental or toiletry purposes
- A61K47/6929Preparations for medical, dental or toiletry purposes
- A61K47/6923Preparations for medical, dental or toiletry purposes
- A61K33/243Preparations for medical, dental or toiletry purposes
- A61K47/02Preparations for medical, dental or toiletry purposes
- B82Y5/00Specific uses or applications of nanostructures; measurement or analysis of nanostructures; manufacture or treatment of nanostructures
Inventors
Inventors
- First inventorHassan A. Rudayni
- InventorAhmed Aly Allam
- InventorAya Fadlallah Abdelmonem Mohamed
- InventorMostafa R. Abukhadra
- InventorNohan Nasser Abdelfattah Ahmed
Keywords
Keywords
- glauconite
- silicate nanorods
- cisplatin
- drug delivery
- controlled release
- clay nanomaterial
- sonication
- in-vitro oncology
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.